Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Vuppalanchi, Raj ^a   Liang, Tiebing ^a   Goswami, Chirayu Pankaj ^a   Nalamasu, Rohit ^a   Li, Lang ^a   Jones, David ^a   Wei, Rongrong ^b   Liu, Wanqing ^b   Sarasani, Vishal ^a   Janga, Sarath Chandra ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; MICRORNA; MICRORNA 155; MICRORNA 181D; MICRORNA 454; MICRORNA 500; MICRORNA 582 5P; MICRORNA LET 7F 1; MIDAZOLAM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; ENZYME ACTIVITY; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER MICROSOME; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

3' UNTRANSLATED REGIONS; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DEMOGRAPHY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MICRORNAS; MIDDLE AGED; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 84884126914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074471     Document Type: Article

References (49)

1. Verbeeck RK, (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64: 1147-1161. doi:10.1007/s00228-008-0553-z. PubMed: 18762933.
2. Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling Food and Drug Administration website. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf. Accessed 2013 July 4.
3. Morgan DJ, McLean AJ, (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 29: 370-391. doi:10.2165/00003088-199529050-00005. PubMed: 8582120.
4. Rodighiero V, (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37: 399-431. doi:10.2165/00003088-199937050-00004. PubMed: 10589374.
5. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, et al. (2006) Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther 80: 235-245. doi:10.1016/j.clpt.2006.05.006. PubMed: 16952490.
6. Iqbal S, Vickers C, Elias E, (1990) Drug metabolism in end-stage liver disease. In vitro activities of some phase I and phase II enzymes. J Hepatol 11: 37-42. doi:10.1016/0168-8278(90)91484-E. PubMed: 2398265.
7. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, et al. (2000) The human CYP3A subfamily: practical considerations. Drug Metab Rev 32: 339-361. doi:10.1081/DMR-100102338. PubMed: 11139133.
8. Lamba JK, Lin YS, Schuetz EG, Thummel KE, (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54: 1271-1294. doi:10.1016/S0169-409X(02)00066-2. PubMed: 12406645.
9. Elbekai RH, Korashy HM, El-Kadi AO, (2004) The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 5: 157-167. doi:10.2174/1389200043489054. PubMed: 15078193.
10. Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, et al. (2003) Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 9: 359-363. PubMed: 12532467.
11. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM, (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193-209. doi:10.1016/j.taap.2004.01.010. PubMed: 15364537.
12. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, et al. (1992) The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51: 229-238. doi:10.1038/clpt.1992.17. PubMed: 1544283.
13. George J, Liddle C, Murray M, Byth K, Farrell GC, (1995) Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49: 873-881. doi:10.1016/0006-2952(94)00515-N. PubMed: 7741759.
14. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE, (2001) Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 34: 1103-1108. doi:10.1053/jhep.2001.29306. PubMed: 11731998.
15. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102: 1016-1023. doi:10.1172/JCI3703. PubMed: 9727070.
16. Goodwin B, Hodgson E, Liddle C, (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56: 1329-1339. PubMed: 10570062.
17. Liu FJ, Song X, Yang D, Deng R, Yan B, (2008) The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. Biochem J 409: 243-250. doi:10.1042/BJ20070613. PubMed: 17764444.
18. Toriyabe T, Nagata K, Takada T, Aratsu Y, Matsubara T, et al. (2009) Unveiling a new essential cis element for the transactivation of the CYP3A4 gene by xenobiotics. Mol Pharmacol 75: 677-684. doi:10.1124/mol.108.050575. PubMed: 19074998.
19. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C, (2002) Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 62: 359-365. doi:10.1124/mol.62.2.359. PubMed: 12130689.
20. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, et al. (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978-988. doi:10.1053/jhep.2003.50393. PubMed: 14512885.
21. Takagi S, Nakajima M, Mohri T, Yokoi T, (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283: 9674-9680. doi:10.1074/jbc.M709382200. PubMed: 18268015.
22. Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, et al. (2012) DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie 94: 2338-2344. doi:10.1016/j.biochi.2012.07.013. PubMed: 22906825.
23. Klein K, Thomas M, Winter S, Nussler AK, Niemi M, et al. (2012) PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther 91: 1044-1052. doi:10.1038/clpt.2011.336. PubMed: 22510778.
24. Aitken AE, Morgan ET, (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35: 1687-1693. doi:10.1124/dmd.107.015511. PubMed: 17576808.
25. Takagi S, Nakajima M, Kida K, Yamaura Y, Fukami T, et al. (2010) MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. J Biol Chem 285: 4415-4422. doi:10.1074/jbc.M109.085431. PubMed: 20018894.
26. Ramamoorthy A, Li L, Gaedigk A, Bradford LD, Benson EA, et al. (2012) In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4alpha expression. Drug Metab Dispos 40: 726-733. doi:10.1124/dmd.111.040329. PubMed: 22232426.
27. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, Goldstein JA, (2012) Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol 82: 529-540. doi:10.1124/mol.112.078386. PubMed: 22723340.
28. Wang Z, Burke PA, (2013) The role of microRNAs in hepatocyte nuclear factor-4alpha expression and transactivation. Biochim Biophys Acta 1829: 436-442. doi:10.1016/j.bbagrm.2012.12.009. PubMed: 23298640.
29. Ramamoorthy A, Skaar TC, (2011) In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes. Drugs Metab Lett 5: 126-131. doi:10.2174/187231211795305258. PubMed: 21457141.
30. Nakajima M, Yokoi T, (2011) MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther 131: 330-337. doi:10.1016/j.pharmthera.2011.04.009. PubMed: 21565218.
31. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T, (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66: 9090-9098. doi:10.1158/0008-5472.CAN-06-1403. PubMed: 16982751.
32. Pan YZ, Gao W, Yu AM, (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37: 2112-2117. doi:10.1124/dmd.109.027680. PubMed: 19581388.
33. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, et al. (2010) Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79: 1045-1052. doi:10.1016/j.bcp.2009.11.015. PubMed: 19945440.
34. Wang Y, Hu HH, Pang H, Zhou XY, Yu LS, et al. (2012) Lentiviral transgenic microRNA-based shRNA suppressed mouse cytochromosome P450 3A (CYP3A) expression in a dose-dependent and inheritable manner. PLOS ONE 7: e30560. doi:10.1371/journal.pone.0030560. PubMed: 22291988.
35. Gorski JC, Jones DR, Wrighton SA, Hall SD, (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contrib Cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48: 173-182.
36. Liang T, Kimpel MW, McClintick JN, Skillman AR, McCall K, et al. (2010) Candidate genes for alcohol preference identified by expression profiling in alcohol-preferring and-nonpreferring reciprocal congenic rats. Genome Biol 11: R11. doi:10.1186/gb-2010-11-2-r11. PubMed: 20128895.
37. Liang T, Habegger K, Spence JP, Foroud T, Ellison JA, et al. (2004) Glutathione S-transferase 8-8 expression is lower in alcohol-preferring than in alcohol-nonpreferring rats. Alcohol Clin Exp Res 28: 1622-1628. doi:10.1097/01.ALC.0000145686.79141.57. PubMed: 15547447.
38. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, et al. (2013) Ensembl 2013. Nucleic Acids Res 41: D48-D55. doi:10.1093/nar/gks1236. PubMed: 23203987.
39. Kozomara A, Griffiths-Jones S, (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39: D152-D157. doi:10.1093/nar/gkr817. PubMed: 21037258.
40. Betel D, Koppal A, Agius P, Sander C, Leslie C, (2010) Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 11: R90. doi:10.1186/gb-2010-11-8-r90. PubMed: 20799968.
41. Abril JF, Guigó R, (2000) gff2ps: visualizing genomic annotations. Bioinformatics 16: 743-744. doi:10.1093/bioinformatics/16.8.743. PubMed: 11099262.
42. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, et al. (2010) Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437-1446. doi:10.1038/labinvest.2010.113. PubMed: 20548288.
43. Pottier N, Maurin T, Chevalier B, Puisségur MP, Lebrigand K, et al. (2009) Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLOS ONE 4: e6718. doi:10.1371/journal.pone.0006718. PubMed: 19701459.
44. Vettori S, Gay S, Distler O, (2012) Role of MicroRNAs in Fibrosis. Open Rheumatol J 6: 130-139. doi:10.2174/1874312901206010130. PubMed: 22802911.
45. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, et al. (2012) Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56: 1946-1957. doi:10.1002/hep.25873. PubMed: 22684891.
46. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, et al. (2012) Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 138: 153-161. doi:10.1007/s00432-011-1076-z. PubMed: 22071603.
47. Bala S, Marcos M, Kodys K, Csak T, Catalano D, et al. (2011) Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 286: 1436-1444. doi:10.1074/jbc.M110.145870. PubMed: 21062749.
48. Bala S, Szabo G, (2012) MicroRNA Signature in Alcoholic Liver Disease. Int J Hepatol(2012): pp. 498232. PubMed: 22518321.
49. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, et al. (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31: 755-761. doi:10.1124/dmd.31.6.755. PubMed: 12756208.